BTIG analyst Ryan Zimmerman upgraded GE HealthCare to Buy from Neutral with a $100 price target. After a “tough” first half of 2024 where China hurt results, the setup for GE HealthCare has improved, the analyst tells investors in a research note. The firm says the company’s guidance was reduced to effectively remove any benefit from Chinese government stimulus and now assumes declines in the Chinse market of over 20%. GE HealthCare enters the second half of 2024 with a lower bar and faces easier compares in the first half of 2024, contends BTIG.